Evolus (EOLS) to Release Quarterly Earnings on Wednesday

Evolus (NASDAQ:EOLS) is set to issue its quarterly earnings data after the market closes on Wednesday, November 6th. Analysts expect the company to announce earnings of ($0.08) per share for the quarter. Parties interested in registering for the company’s conference call can do so using this link.

Evolus Trading Up 2.6 %

Evolus stock opened at $16.75 on Monday. Evolus has a 52 week low of $7.67 and a 52 week high of $17.82. The company has a debt-to-equity ratio of 6.26, a quick ratio of 2.67 and a current ratio of 2.92. The firm has a market capitalization of $1.06 billion, a price-to-earnings ratio of -18.41 and a beta of 1.31. The company has a 50 day moving average price of $16.25 and a 200 day moving average price of $13.72.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on EOLS shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of Evolus in a report on Monday, September 16th. Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 target price on shares of Evolus in a research note on Friday, September 13th. HC Wainwright reissued a “buy” rating and issued a $27.00 price target on shares of Evolus in a research report on Friday. Finally, Barclays raised their price target on shares of Evolus from $16.00 to $20.00 and gave the stock an “overweight” rating in a report on Friday, September 13th.

Insider Buying and Selling at Evolus

In other news, CFO Sandra Beaver sold 3,276 shares of the stock in a transaction on Friday, September 6th. The shares were sold at an average price of $14.98, for a total transaction of $49,074.48. Following the transaction, the chief financial officer now owns 148,502 shares in the company, valued at $2,224,559.96. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Evolus news, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the company’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $15.85, for a total transaction of $89,251.35. Following the completion of the sale, the chief marketing officer now owns 82,375 shares of the company’s stock, valued at $1,305,643.75. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Sandra Beaver sold 3,276 shares of the stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $14.98, for a total value of $49,074.48. Following the transaction, the chief financial officer now owns 148,502 shares in the company, valued at approximately $2,224,559.96. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 6.10% of the company’s stock.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.